| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC2886 | K103 Hydrochloride | Novel inhibitor of peptidoglycan synthesis targeting the lipid II precursor |
|
| DCC2887 | K-14585 | Novel antagonist for proteinase-activated receptor 2 (PAR2) |
|
| DCC2888 | K4610422 | Novel norditerpenoid inhibitor of testosterone-5α-reductase |
|
| DCC2889 | K-8008 | Novel inhibitor of the interaction of the N-terminally truncated RXR |
|
| DCC2890 | K-8012 | Novel inhibitor of the interaction of the N-terminally truncated RXR |
|
| DCC2891 | Kaempulchraol P | Natural anti-inflammatory agent, inhibiting the NF-κB-mediated transactivation of a luciferase reporter gene, IL-6 production, and COX-2 expression |
|
| DCC2892 | Kaempulchraol Q | Natural anti-inflammatory agent, inhibiting the NF-κB-mediated transactivation of a luciferase reporter gene, IL-6 production, and COX-2 expression |
|
| DCC2893 | Kalb001 | Novel mGlu4 ligand |
|
| DCC2894 | Kar425 | Novel antimalarial agent, providing protection to malaria-infected mice |
|
| DCC2895 | Kasugamycin | Antibiotic, binding within the mRNA channel of the 30S subunit and inhibiting protein synthesis |
|
| DCC2896 | Kb130015 | Novel activator of hERG1 potassium channels, blocking native and recombinant hERG1 channels at high voltages, but activating them at low voltages |
|
| DCC2897 | Kbh-a42 | Novel histone deacetylase inhibitor |
|
| DCC2898 | Kbjk557 | Novel Plk1 PBD inhibitor, showing a remarkable in vitro anticancer effect by inducing Plk1 delocalization, mitotic arrest, and apoptosis in HeLa cells |
|
| DCC2899 | Kb-nb165-09 | Selective inhibitor of Protein_kinase_D1>protein kinase D (PKD); Inhibitor of cell adhesion and HIV; Inhibitor of herpes simplex virus type 1 replication |
|
| DCC2900 | Kbp-088 | Novel highly potent dual amylin and calcitonin receptor agonist (DACRA), showing long-lasting improvement of food preference and body weight loss |
|
| DCC2901 | Kb-r7785 | Novel ADAM12 and MMP inhibitor, ameliorating cardiac function in a transverse aortic constriction (TAC) model by inhibiting the proteolytic activation of HB-EGF signaling, exerting its antidiabetic effect by ameliorating insulin sensitivity through the in |
|
| DCC2902 | Kc-11404 | LTB4 inhibitor for the treatment of b-cell leukemias and lymphomas, potently inhibiting histamine, platelet activating factor,and 5-lipoxygenase |
|
| DCC2903 | Kca075 | Highly specific transglutaminase 2 (TG2) inhibitor |
|
| DCC2904 | Kca-1490 | Dual PDE3/4 inhibitor |
|
| DCC2905 | Kca2 Positive Modulator 2q | Novel potent and Subtype-Selective Positive Modulator of KCa2 Channels |
|
| DCC2906 | Kcal01 | Potent PDZ domain peptide inhibitor that rescues CFTR activity |
|
| DCC2907 | Kdm4c-in-35 | Novel selective KDM4C inhibitor |
|
| DCC2908 | Kdm4-in-i | Novel KDM4 inhibitor |
|
| DCC2909 | Kdoam-20 | Potent and selective KDM5 inhibitor |
|
| DCC2910 | Kdoam-21 | Potent and selective KDM5 inhibitor |
|
| DCC2911 | Kemptide Acetate Salt | Phosphate acceptor peptide substrate for cAMP-dependent protein kinase |
|
| DCC2912 | Kf15372 | Potent and selective adenosine A1 antagonist with renal protective and diuretic activities |
|
| DCC2913 | Kfa1982 | Novel and potent factor Xa inhibitor |
|
| DCC2914 | Kgchm07 | Novel potent peptide dual agonist of opioid/neurokinin 1 receptor |
|
| DCC2915 | Kh-carb13 Hydrochloride | Novel Pim-1 kinase Inhibitor, dose-dependent decreasing the viability of LS174T and HCT-116 cells |
|
